The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
Key takeaways of recent quarter & conference call highlights
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Subscribe To Our Newsletter & Stay Updated
